A phase i study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas

International Journal of Radiation Oncology Biology Physics

Volumn 85, Issue 2, 2013, Pages 321-328

  Den, Robert B ^a   Kamrava, Mitchell ^b   Sheng, Zhi ^c   Werner Wasik, Maria ^a   Dougherty, Erin ^a   Marinucchi, Michelle ^a   Lawrence, Yaacov R ^a,d   Hegarty, Sarah ^a   Hyslop, Terry ^a   Andrews, David W ^a   Glass, Jon ^a   Friedman, David P ^a   Green, Michael R ^c   Camphausen, Kevin ^b   Dicker, Adam P ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AFTER-TREATMENT; ANTI-ANGIOGENIC THERAPY; CELL VIABILITY; CLINICAL TRIAL; DOSE ESCALATION; GLIOMA CELL LINES; HIGH-GRADE GLIOMAS; MAXIMUM TOLERATED DOSE; OVERALL SURVIVAL; PHASE I; PHASE II; PRECLINICAL STUDIES; RADIATION MONOTHERAPY; RECURRENT GLIOMAS; SORAFENIB; TEMOZOLOMIDE;

CELL CULTURE; RADIOTHERAPY; TOXICITY; TUMORS;

RADIATION;

SORAFENIB; TEMOZOLOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; BACTEREMIA; BLOOD TOXICITY; CANCER CELL CULTURE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GLIOBLASTOMA; GLIOSARCOMA; HEART PALPITATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOGLYCEMIA; HYPOKALEMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; NEUROPATHY; OLIGODENDROGLIOMA; OPEN STUDY; OVERALL SURVIVAL; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL; PHOTOSENSITIVITY; PRIMARY TUMOR; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RASH; RECOMMENDED DRUG DOSE; RECURRENT CANCER; SIDE EFFECT; SPINAL CORD DISEASE; STEREOTACTIC RADIOSURGERY; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CHEMORADIOTHERAPY; DACARBAZINE; FEMALE; GLIOMA; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NIACINAMIDE; PHENYLUREA COMPOUNDS; RADIOTHERAPY DOSAGE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84872198988     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.04.017     Document Type: Article

References (16)

1. R. Stupp, W.P. Mason, and M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
2. J.J. Vredenburgh, A. Desjardins, and J.E. Herndon 2nd Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 2007 4722 4729
3. J.L. Chan, S.W. Lee, and B.A. Fraass Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy J Clin Oncol 20 2002 1635 1642
4. S.E. Fogh, D.W. Andrews, and J. Glass Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas J Clin Oncol 28 2010 3048 3053
5. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
6. J.M. Llovet, S. Ricci, and V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
7. A.W. Suen, S. Galoforo, and B. Marples Sorafenib and radiation: a promising combination in colorectal cancer Int J Radiat Oncol Biol Phys 78 2010 213 220
8. X.H. Ma, S. Piao, and D. Wang Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma Clin Cancer Res 17 2011 3478 3489
9. D.A. Reardon, J.J. Vredenburgh, and A. Desjardins Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma J Neurooncol 101 2011 57 66
10. J.D. Hainsworth, T. Ervin, and E. Friedman Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme Cancer 116 2010 3663 3669
11. Z. Sheng, L. Li, and L.J. Zhu A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications Nat Med 16 2010 671 677
12. Z. Sheng, S.Z. Wang, and M.R. Green Transcription and signalling pathways involved in BCR-ABL-mediated misregulation of 24p3 and 24p3R EMBO J 28 2009 866 876
13. H.S. Friedman, M.D. Prados, and P.Y. Wen Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 2009 4733 4740
14. T.T. Batchelor, D.G. Duda, and E. di Tomaso Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma J Clin Oncol 28 2010 2817 2823
15. A. Narayana, J.G. Golfinos, and I. Fischer Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma Int J Radiat Oncol Biol Phys 72 2008 383 389
16. J. Drappatz, A.D. Norden, and E.T. Wong Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma Int J Radiat Oncol Biol Phys 78 2010 85 90